KAIO Therapy, LLC develops an Immune Activating Heat Therapy (IAHT) technology designed to treat cancer patients by combining hyperthermia with immunotherapy. The system utilizes injected nanoparticles and an alternating magnetic field device to induce controlled heat within tumors, which destroys cancer cells and activates the patient's immune system against primary and metastatic tumors.
Subscribe to see KAIO Therapy, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
KAIO Therapy, LLC is a biotechnology company headquartered in Raleigh, United States. It has raised at least $31.1M across the 4 funding rounds on record, 3 of them with a disclosed amount. Its most recent funding round raised $897,204 in September 2020. Xcout tracks 7 named people at KAIO Therapy, LLC, including Peter Geiger (Chief Financial Officer).
As of 16 November 2026. Source: Xcout Intel.
1 more named person on record for KAIO Therapy, LLC, with roles, board committees and tenure — see the full roster →
At least $31.1M raised across the 4 rounds on record (3 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $897,204 | — | |
| Series A | $30M | 4 named | |
| SEC Form D filing | $200,000 | — | |
| — | Undisclosed | 7 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A funding-flow diagram of the 7 named investors across 2 rounds: who backed which round, who led it, and who came back for the next one.
Sign in to see it, or subscribe for the full funding history →
A few of KAIO Therapy, LLC's closest competitors — see the full list of competitors and alternatives →
Haniva Technology LLC is a biotechnology company that develops patented combination therapies and drug delivery devices to treat various forms of cancer. Its research focuses on using non-thermal plasma alongside hypoxia-activated DNA-damaging agents to selectively target and reduce tumor volume, prevent metastasis, and serve as an adjuvant treatment following tumor resection.
Kortuc Inc. develops cancer radiotherapy solutions, specifically offering an innovative radiosensitizer designed to eliminate tumor hypoxia and maximize the effectiveness of radiation treatment. The company serves the medical and oncology research sectors by advancing clinical trials and expanding treatment options for cancer patients.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
Oleander Medical Technologies is developing a cancer treatment called Targeted Osmotic Lysis (TOL), which destroys malignant cells by forcing them to absorb excessive sodium and burst. The therapy combines an existing heart medication with an investigational pulsed electric field device to target cancers with elevated sodium channel expression while leaving healthy cells unharmed.
Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development of therapies using Tumor Treating Fields.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about KAIO Therapy, LLC? Suggest a correction · Work at KAIO Therapy, LLC? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.